Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on "Dr.
Reddy's and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India."
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
Dr. Reddy's and RDIF receive approval
to conduct clinical trial for Sputnik V vaccine in India
Hyderabad, India, October 17, 2020: Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, today
announced that they have received approval from the Drug Control General of India (DCGI) to conduct an adaptive phase 2/3 human
clinical trial for Sputnik V vaccine in India. This will be a multi-center and randomized controlled study, which will include
safety and immunogenicity study.
Earlier in September 2020, Dr. Reddy's and RDIF entered into
a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall
supply 100 million doses of the vaccine to Dr. Reddy's upon regulatory approval in India.
G V Prasad, Co-chairman and Managing Director, Dr. Reddy's
Laboratories, said "This is a significant development that allows us to commence the clinical trial in India and we are committed
to bringing in a safe and efficacious vaccine to combat the pandemic."
Kirill Dmitriev, CEO of the Russian Direct Investment Fund,
said, "We are pleased to collaborate with the Indian regulators and in addition to Indian clinical trial data, we will provide
safety and immunogenicity study from the Russian phase 3 clinical trial. This data will further strengthen the clinical development
of Sputnik V vaccine in India."
On August 11, 2020, the Sputnik V vaccine developed by the Gamaleya
National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the
world's first registered vaccine against COVID-19 based on the human adenoviral vectors platform. Sputnik V is currently
undergoing phase 3 clinical trial in Russia and the proposed number of subjects is 40,000. Additionally, phase 3 clinical trial
of the vaccine has commenced in the UAE last week.
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd.
(BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics
and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical
services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,
diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets
include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Russian Direct Investment Fund (RDIF) is Russia's sovereign
wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial
and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF's management company
is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign
partners totaling more than RUB1.9 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ
more than 800,000 people and generate revenues which equate to more than 6% of Russia's GDP. RDIF has established joint strategic
partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information
can be found at www.rdif.ru
Russian Direct Investment Fund
Arseniy Palagin, Press Secretary
Tel: +44 (0) 20 7796 4133 Tel: +7 495 644 34 14, ext. 2395 Mobile:
+7 916 110 31 41 E-mail: arseniy.palagin@rdif.ru